<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05021588</url>
  </required_header>
  <id_info>
    <org_study_id>anticoagulant in covid19</org_study_id>
    <nct_id>NCT05021588</nct_id>
  </id_info>
  <brief_title>Steroid and Anticoagulant Therapy in covid19</brief_title>
  <acronym>SARS-CoV-2</acronym>
  <official_title>Challenges in Steroid and Anticoagulant Therapy in Severe COVID-19 Pneumonia: A Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      As COVID-19 has neither standard treatment protocol nor guidelines, there are many treatment&#xD;
      protocols foranti-inflammatory corticosteroids and anti-coagulations for severe COVID-19&#xD;
      pneumonia patients. This study aimed to assess the most suitable modality in this high-risk&#xD;
      group.&#xD;
&#xD;
      Methods: A prospective, experimental study design was adopted, that included 123 severe&#xD;
      COVID-19 pneumonia patientsadmitted at Assiut UniversityHospital from April 10th, 2020, to&#xD;
      September10th, 2020. Patients were divided into 3 groups according to a combined&#xD;
      corticosteroid and anticoagulants therapy protocols. Group A included 32 patients, group B&#xD;
      included 45 patients, and group C included 46 patients. Assessment of cases was conducted&#xD;
      according to the treatment type and duration, weaning duration from oxygen therapy, length of&#xD;
      hospital and ICU stay, and complications during treatment.Three months follow up after&#xD;
      discharge was performed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 12, 2020</start_date>
  <completion_date type="Actual">September 10, 2020</completion_date>
  <primary_completion_date type="Actual">August 2, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Outcome of patients after corticosteroids and anti-coagulants for severe COVID-19 pneumonia</measure>
    <time_frame>5 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">123</enrollment>
  <condition>Pneumonia, Viral</condition>
  <arm_group>
    <arm_group_label>Group A:dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: prednisolone or methyl prednisolone according to D-dimer levels.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C: prednisolone or methylprednisolone and anticoagulants according to the flexible protocol.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>steroid and anticoagulants according to different protocols.</intervention_name>
    <description>As no standard treatment for COVID-19 was approved; there are many treatment protocols for anti-inflammatory corticosteroids and anti-coagulantsfor severe COVID-19 pneumonia cases, this study aims to assess the most suitable modality in this high-risk group.</description>
    <arm_group_label>Group A:dexamethasone</arm_group_label>
    <arm_group_label>Group B: prednisolone or methyl prednisolone according to D-dimer levels.</arm_group_label>
    <arm_group_label>Group C: prednisolone or methylprednisolone and anticoagulants according to the flexible protocol.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  respiratory distress [respiratory rate (RR) &gt;30 breaths/min at rest], mean oxygen&#xD;
             saturation ≤93%,ratio of arterial oxygen partial pressure to fractional inspired&#xD;
             oxygen (PaO2/FiO2) ≤300 mmHg,&gt;50% lung involvement on imaging within 24 to 48 hours of&#xD;
             admission&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pnumonia not caused by covid19&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Marwarady</name>
      <address>
        <city>Asyut</city>
        <zip>11711</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 16, 2021</study_first_submitted>
  <study_first_submitted_qc>August 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2021</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Marwa mahmoud Abd El Rady</investigator_full_name>
    <investigator_title>lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Viral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

